



BlueCross BlueShield
of Alabama

Name of Blue Advantage Policy:

Radiofrequency Ablation of Solid Tumors Excluding Liver Tumors

Policy #: 119

Latest Review Date: September 2023

Category: Surgery

BACKGROUND:

Blue Advantage medical policy does not conflict with Local Coverage Determinations (LCDs), Local Medical Review Policies (LMRPs) or National Coverage Determinations (NCDs) or with coverage provisions in Medicare manuals, instructions or operational policy letters. In order to be covered by Blue Advantage the service shall be reasonable and necessary under Title XVIII of the Social Security Act, Section 1862(a)(1)(A). The service is considered reasonable and necessary if it is determined that the service is:

1. *Safe and effective;*
2. *Not experimental or investigational*;*
3. *Appropriate, including duration and frequency that is considered appropriate for the service, in terms of whether it is:*
 - *Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient's condition or to improve the function of a malformed body member;*
 - *Furnished in a setting appropriate to the patient's medical needs and condition;*
 - *Ordered and furnished by qualified personnel;*
 - *One that meets, but does not exceed, the patient's medical need; and*
 - *At least as beneficial as an existing and available medically appropriate alternative.*

Routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000 which meet the requirements of the Clinical Trials NCD are considered reasonable and necessary by Medicare. Providers should bill **Original Medicare for covered services that are related to **clinical trials** that meet Medicare requirements (Refer to Medicare National Coverage Determinations Manual, Chapter 1, Section 310 and Medicare Claims Processing Manual Chapter 32, Sections 69.0-69.11).*

POLICY:

Blue Advantage will treat **radiofrequency ablation** as a **covered benefit** for the treatment of individuals with the following conditions:

- Renal cell carcinoma
 - In order to preserve kidney function in individuals with significantly impaired renal function (i.e., the individual has one kidney or renal insufficiency defined by a glomerular filtration rate [GFR] of less than 60mL/min/m²) when the standard surgical approach (i.e., resection of renal tissue) is likely to substantially worsen existing kidney function

OR

- The individual is not considered a surgical candidate
- Osteoid osteomas that cannot be managed successfully with medical treatment
- Osteolytic bone metastases that have failed or are poor candidates for standard treatments such as radiation or opioids
- Isolated peripheral non-small cell lung cancer lesion $\leq 3\text{cm}^*$,

AND

- Surgical resection or radiation treatment with curative intent is considered appropriate based on stage of disease, however, medical co-morbidity renders the individual unfit for those interventions;

AND

- Tumor is located at least 1 cm from the trachea, main bronchi, esophagus, aorta, aortic arch branches, pulmonary artery and the heart.
- Malignant non-pulmonary tumor(s) metastatic to the lung $\leq 3\text{cm}^*$,

AND

- In order to preserve lung function when surgical resection or radiation treatment is likely to substantially worsen pulmonary status OR the individual is not considered a surgical candidate;

AND

- There is no evidence of extrapulmonary metastases;

AND

- Tumor is located at least 1 cm from the trachea, main bronchi, esophagus, aorta, aortic arch branches, pulmonary artery and the heart.

*No more than 3 tumors per lung should be ablated; tumors should be amenable to complete ablation; and twelve months should elapse before a repeat ablation is considered.

Blue Advantage will treat **radiofrequency ablation** as a **non-covered benefit** and as **investigational** as a technique for ablation of:

- Renal cell cancer not meeting the criteria above
- Osteoid osteomas that can be managed with medical treatment
- Painful bony metastases as initial treatment
- Lung cancer not meeting the above criteria
- Breast tumors
- Other tumors outside the liver, including but not limited to the head and neck, thyroid, adrenal gland, ovary, and pelvis/abdominal metastases of unspecified origin.

Please refer to Blue Advantage Policy #178 for coverage information on ultrasound ablation of the bone

Please refer to Blue Advantage Policy #429 for coverage information on cryosurgical ablation of renal, bone, and pulmonary tumors

Please refer to Blue Advantage NCD for Cryosurgery of Prostate (230.9)

Please refer to Blue Advantage Policy #070 for coverage information on locoregional therapies for liver tumors

Please refer to Policy# 596 for coverage information on focal treatments for prostate cancer.

Blue Advantage does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. Blue Advantage administers benefits based on the members' contract and medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.

DESCRIPTION OF PROCEDURE OR SERVICE:

Health Disparities in Certain Solid Tumor Types

Based on data from 2014 through 2018, age-adjusted breast cancer mortality is approximately 40% higher among Black women compared to non-Hispanic White women in the United States (27.7 vs 20.0 deaths per 100,000 women), despite a lower overall incidence of breast cancer among Black women (125.8 vs 139.2 cases per 100,000 women). Experts postulate that this divergence in mortality may be related to access issues— Black women are more likely than White women to lack health insurance, limiting access to screening and appropriate therapies. Socioeconomic status is also a driver in health and health outcome disparities related to breast cancer. Women with low incomes have significantly lower rates of breast cancer screening, a higher probability of late-stage diagnosis, and are less likely to receive high-quality care, resulting in higher mortality from breast cancer.

Based on data from 2016 through 2020, kidney cancer is more common in men than women and occurs more often in American Indian and Alaskan Native individuals, followed by Black and Hispanic individuals. American Indians and Alaska Natives have higher death rates from kidney cancer than any other racial or ethnic group. A cohort study by Howard et al (2021) included 158,445 patients with localized kidney cancer from the National Cancer Database between 2010 and 2017. Investigators found that female patients were treated more aggressively compared with male patients, with lower adjusted odds of undertreatment and higher adjusted odds of overtreatment. They also found that Black and Hispanic patients had higher adjusted odds of undertreatment and overtreatment compared to White patients, and uninsured status was associated with lower adjusted odds of overtreatment and higher adjusted odds of undertreatment. These results suggest that sex, race and ethnicity, and socioeconomic status are associated with disparities in guideline-based treatment for localized kidney cancer, specifically,

with increased rates of non-guideline-based treatment for women and Black and Hispanic patients.

In radiofrequency ablation (RFA), a probe is inserted into the center of a tumor; then, prong-shaped, non-insulated electrodes are projected into the tumor. Next, heat is generated locally by an alternating, high-frequency current that travels through the electrodes. The localized heat treats the tissue adjacent to the probe, resulting in a 3 cm to 5.5 cm sphere of dead tissue. The cells killed by RFA are not removed but are gradually replaced by fibrosis and scar tissue. If there is a local recurrence, it occurs at the edge and can sometimes be retreated. RFA may be performed percutaneously, laparoscopically, or as an open procedure.

Renal Cell Carcinoma (RCC)

Radical nephrectomy remains the principal treatment of RCC, however, partial nephrectomy or nephron-sparing surgery has been shown to be as effective as radical nephrectomy, with comparable long-term recurrence-free survival rates, in a select group of patients. Alternative therapy such as RFA is of interest in patients with small renal tumors when preservation of renal function is necessary (e.g., in patients with marginal renal function, a solitary kidney, bilateral tumors) and in patients with comorbidities that would render them unfit for surgery. Another consideration would be in patients at high risk of developing additional renal cancers (as in von Hippel-Lindau disease).

Osteolytic Bone Metastases

After lung and liver, bone is the third most common metastatic site and is relatively frequent among patients with primary malignancies of the breast, prostate, and lung. Bone metastases often cause osteolysis (bone breakdown), resulting in pain, fractures, decreased mobility, and reduced quality of life. External-beam irradiation often is the initial palliative therapy for osteolytic bone metastases. However, pain from bone metastases is refractory to radiation therapy in 20 to 30% of patients, while recurrent pain at previously irradiated sites may be ineligible for additional radiation due to risks of normal tissue damage. Other alternatives include hormonal therapy, radiopharmaceuticals such as strontium 89, and bisphosphonates. Less often, surgery or chemotherapy may be used for palliation, and intractable pain may require opioid medications. RFA has been investigated as another alternative for palliating pain from bone metastases.

Osteoid Osteomas

Osteomas are the most common benign bone tumor, comprising 10–20% of benign and 2–3% of all bone tumors. They are typically seen in children and young adults, with most diagnosed in patients between five to 20 years of age. Osteomas are most common in the lower extremity (usually the long bones, mainly the femur) and less common in the spine. These tumors typically have a characteristic clinical presentation and radiologic appearance, with pain, usually continuous and worse at night, and usually relieved by aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). The natural history of the osteoid osteoma varies based upon its location, and although they rarely exceed 1.5cm, may produce bone widening and deformation, limb length inequality, or angular deviations when near a growth plate. When located in the

spine, these lesions may lead to painful scoliosis or torticollis. Sometimes, they heal spontaneously after three to seven years.

Treatment options include medical management with nonsteroidal anti-inflammatory drugs (NSAIDs), surgical excision (wide/en bloc excision or curetting), or the use of CT- or magnetic resonance imaging (MRI)-guided minimally invasive procedures including core drill excision, laser photocoagulation, or RFA. For many years, complete surgical excision was the classic treatment of osteomas, usually performed in patients with pain despite medical management. Complete surgical excision has several disadvantages. A substantial incision may be necessary and removal of a considerable amount of bone (especially in the neck of the femur), increases the need for bone grafting and/or internal fixation (which often necessitates a second procedure to remove the metal work). Other possible risks include avascular necrosis of the femoral head and postoperative pathologic fracture. In addition, surgical excision leads to a lengthier period of convalescence and postoperative immobilization. Anatomically inaccessible tumors may not be completely resectable and may recur. RFA of osteoid osteoma is done with a needle puncture, so no incision or sutures are needed, and patients may immediately walk on the treated extremity and return to daily activities as soon as the anesthetic effect wears off. The risk of recurrence with RFA of an osteoma is 5 to 10%, and recurrent tumors can be retreated with RFA. In general, RFA is not performed in many spinal osteomas because of possible thermal-related nerve damage.

Primary Pulmonary Tumors and Metastases

Surgery is the current treatment of choice in patients with Stage I primary non-small cell lung carcinoma (NSCLC). (Stage I includes Ia: T1N0M0 and Ib: T2N0M0). Only approximately 20% of patients present with Stage I disease, although this number is expected to increase as a result of screening programs, advances in imaging modalities, and widespread use of CT scans for other indications. Postsurgical recurrence rates of Stage I NSCLC have been reported between 20% and 30%, with most occurring at distant sites; locoregional recurrences occur in approximately 12%. Large differences in survival outcome are observed after surgery in Stage I patients, with five-year overall survival (OS) rates, ranging from 77% for small T1 tumors to 35% for large T2 tumors. Untreated, Stage I NSCLC has a five-year OS rate of 6–14%.

Patients with early stage NSCLC who are not surgical candidates may be candidates for radiation treatment with curative intent. In the two largest retrospective radiation therapy series, patients with inoperable disease treated with definitive radiation therapy achieved five-year survival rates of 10% and 27%. In both studies, patients with T1N0 tumors had better five-year survival rates of 60% and 32%, respectively.

Stereotactic whole body radiation therapy (SBRT) has gained more widespread use, as it is a high-precision mode of therapy that allows for delivery of very high doses of radiation. Two- to three-year local control rates of Stage I NSCLC with SBRT have ranged from 80 to 95%. SBRT has been investigated in patients unfit to undergo surgery, with survival rates similar to surgical outcomes.

RFA is being investigated in patients who are medically inoperable, with small primary lung cancers or lung metastases.

Breast Tumors

The treatment of small breast cancers has evolved from total mastectomy toward more conservative treatment options such as lumpectomy, with more acceptable cosmetic outcomes and preservation of the breast. The selection of surgical approach balances the patient's desire for breast conservation and the need for tumor-free margins in resected tissue. Minimally invasive nonsurgical techniques such as RFA are appealing if they can produce local control and survival equivalent to breast-conserving surgical alternatives. Nonsurgical ablative techniques pose difficulties such as the inability to determine tumor size, complete tumor cell killing, and local recurrence. Additionally, RFA can cause burning of the skin or damage to muscle, possibly limiting use in patients with tumors near the skin or chest wall.

Thyroid Tumors

Surgical resection is the primary treatment choice for medically unresponsive, symptomatic benign thyroid tumors and thyroid carcinomas. However, techniques for ablation of thyroid tumors (e.g. RFA, microwave ablation) are being investigated.

Miscellaneous Tumors

Radiofrequency ablation has been investigated for use in individuals with different lesions in different anatomic sites. This includes, but is not limited to, breast and head and neck.

Head and Neck Cancer

In patients with head and neck cancer with recurrent disease, surgical salvage attempts are poor in terms of local control, survival, and quality of life, and these recurrent tumors are often untreatable with standard salvage therapies. Palliative chemotherapy or comfort measures may be offered. The safety and efficacy of RFA has been investigated as an option for palliative treatment in these situations.

Radiofrequency Ablation

Radiofrequency ablation (RFA) was initially developed to treat inoperable tumors of the liver. Recently, studies have reported on the use of RFA to treat other tumors. For some of these, RFA is being investigated as an alternative to surgery for operable tumors. Well-established local or systemic treatment alternatives are available for each of these malignancies. The hypothesized advantages of RFA for these cancers include improved local control and those common to any minimally invasive procedure (eg, preserving normal organ tissue, decreasing morbidity, decreasing length of hospitalization).

Goals of RFA may include (1) controlling local tumor growth and preventing recurrence; (2) palliating symptoms; and (3) extending survival duration for patients with certain tumors. The effective volume of RFA depends on the frequency and duration of applied current, local tissue characteristics, and probe configuration (eg, single vs multiple tips). RFA can be performed as an open surgical procedure, laparoscopically or percutaneously, with ultrasound or computed tomography guidance.

Potential complications associated with RFA include those caused by heat damage to normal tissue adjacent to the tumor (eg, intestinal damage during RFA of kidney), structural damage

along the probe track (eg, pneumothorax as a consequence of procedures on the lung), and secondary tumors (if cells seed during probe removal).

KEY POINTS:

The most recent literature search was performed through August 7, 2023.

Summary of Evidence:

For individuals who have localized renal cell carcinoma (RCC) that is no more than 4 cm in size who receive RFA, the evidence includes a randomized controlled trial (RCT), numerous observational studies, and systematic reviews of these studies. Relevant outcomes are overall survival (OS), change in disease status, QOL, and treatment-related morbidity. A recent meta-analysis that included only an RCT and cohort studies found that RFA was as effective as nephrectomy for small renal tumors, with a reduction in complications. Another recent meta-analysis found that partial nephrectomy (PN) was superior to ablative techniques (the study included RFA but also cryoablation and microwave ablation) in overall mortality and local recurrence but not in cancer-specific mortality. It also found fewer complications and improved renal function with ablation. A meta-analysis from 2022 found that PN was superior to ablation (RFA, cryoablation, and microwave ablation) in local recurrence. Overall complications, decline in renal function, and cancer-specific mortality rates did not differ between ablation and nephrectomy. Although inconsistent, the evidence does suggest that, for small renal tumors, RFA may result in a similar rate of disease progression with a lower complication rate than nephrectomy. However, comparative trials are needed to determine with greater certainty the effects of these treatments in the same patient population. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have painful osteolytic bone metastases who have failed or are poor candidates for standard treatments who receive radiofrequency ablation (RFA), the evidence includes a prospective cohort study and case series. Relevant outcomes are symptoms, change in disease status, quality of life (QOL), medication use, and treatment-related morbidity. A prospective cohort study and case series have shown clinically significant pain relief (defined as a decrease of 2 units from baseline on the Brief Pain Inventory scale) and/or reduction in opioid use following treatment of painful osteolytic metastases. A multicenter, prospective study reported significant reductions in pain through the 6-month follow-up period, with 59% of patients achieving immediate improvement in pain within 3 days of RFA. The population is comprised of patients with few or no treatment options, for whom short-term pain relief is an appropriate clinical outcome. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have painful osteoid osteomas who receive RFA, the evidence includes numerous observational studies and systematic reviews of these studies. Relevant outcomes are symptoms, change in disease status, QOL, medication use, and treatment-related morbidity. In a systematic review of thermal ablation techniques, clinical success (pain-free) was achieved in 94% to 98% of patients. Most patients (89% to 96%) remained pain-free when assessed during longer-term follow-up. Another systematic review reported similar success rates noting an

average 8.3% failure rate among patients receiving computed tomography (CT)-guided RFA. Although no randomized trials of RFA for osteoid osteomas have been performed, the uncontrolled studies have demonstrated RFA can provide adequate symptom relief with minimal complications, for a population for whom short-term symptom relief and avoidance of invasive procedures are appropriate clinical outcomes. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have inoperable primary pulmonary tumors or nonpulmonary tumors metastatic to the lung who receive RFA, the evidence includes prospective observational studies and systematic reviews of these studies. Relevant outcomes are OS, change in disease status, QOL, and treatment-related morbidity. A multicenter study found that for tumors less than 3.5 cm in size, RFA can lead to a complete response in as many as 88% of patients for at least 1 year. Two-year survival rates have been reported to range from 41% to 75% in case series, with 5-year survival rates of 20% to 27%. In general, the evidence suggests that RFA results in adequate survival and tumor control in patients who are not surgical candidates, with low morbidity rates. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have breast tumors who receive RFA, the evidence includes observational studies and systematic reviews of these studies. Relevant outcomes are OS, change in disease status, QOL, and treatment-related morbidity. Evidence has reported varied and incomplete ablation rates with concerns about postablation tumor cell viability. Long-term improvements in health outcomes have not been demonstrated. Additionally, available studies do not permit comparisons with conventional breast-conserving procedures. Further prospective studies, with long-term follow-up, should focus on whether RFA of the breast for small tumors can provide local control and survival rates compared with conventional breast-conserving treatment. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have benign thyroid tumors who receive RFA, the evidence includes RCTs, prospective studies, case series, and systematic reviews of these studies. Relevant outcomes are symptoms, change in disease status, QOL, medication use, and treatment-related morbidity. Systematic reviews have demonstrated that RFA results in a significant reduction in thyroid nodule size with a 2020 review showing that these changes remain durable through at least 36 months. Complication rates are generally low, but include voice changes. The data are limited by significant heterogeneity in meta-analyses, a lack of generalizability to populations outside Republic of Korea and Italy, and a lack of comparators more relevant to practice in the United States. Further studies comparing RFA to percutaneous ethanol injection (PEI) or surgery would be more informative in determining the potential utility of RFA in patients with symptomatic or large benign thyroid tumors as these are the recommended treatment options per the American Thyroid Association. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have miscellaneous tumors (eg, head and neck, thyroid cancer, pancreas) who receive RFA, the evidence includes a few case series, prospective observational studies, and retrospective comparative studies. Relevant outcomes are OS, change in disease status, QOL,

and treatment-related morbidity. There is a limited evidence base for these tumor types. Reporting on outcomes or comparisons with other treatments is limited. These studies do not permit conclusions on the health benefits of RFA. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Practice Guidelines and Position Statements:

American College of Chest Physicians

The American College of Chest Physicians (2013) guidelines on the treatment of stage I and II non-small-cell lung cancer (NSCLC) have indicated RFA has been used effectively in clinical stage I NSCLC. Therefore, in medically inoperable patients, peripheral NSCLC tumors less than 3 cm may be treated with RFA. The College also collaborated with the Society of Thoracic Surgeons to develop consensus guidelines on the treatment of high-risk patients with stage I NSCLC. These 2012 consensus guidelines indicated RFA is an alternative treatment option for patients who are not surgical candidates due to severe medical comorbidity.

American Head and Neck Society - Endocrine Surgery Section

An international, multidisciplinary consensus statement on RFA and related ultrasound-guided ablation technologies for the treatment of benign and malignant thyroid disease was released in 2022 through a collaboration of international professional societies, including the Endocrine Surgery Section of the American Head and Neck Society. Select relevant recommendations from the guideline are listed in Table 1.

Table 1. Summary of RFA Recommendations for Treatment of Benign and Malignant Thyroid Disease*

Recommendation 1	US-guided ablation procedures may be used as a first-line alternative to surgery for patients with benign thyroid nodules contributing to compressive and/or cosmetic symptoms.
Recommendation 2	Although less efficacious than surgery or RAI in normalizing thyroid function, thermal ablation procedures can be a safe therapeutic alternative in patients with an autonomously functional thyroid nodule and contraindications to first-line techniques.
Recommendation 3a	US-guided ablation procedures may be considered in patients with suitable primary papillary microcarcinoma who are unfit for surgery or decline surgery or active surveillance
Recommendation 3b	US-guided ablation procedures may be considered in patients with suitable recurrent papillary thyroid carcinoma who are unfit for surgery or decline surgery or active surveillance
Recommendation 3c	Repeat ablation of a benign nodule can be considered for remnant nodular tissue contributing to unresolved symptomatic or cosmetic concerns

*This is not a comprehensive list of recommendations from the guideline.
RAI: radioactive iodine; RFA: radiofrequency ablation; US: Ultrasound.

American Urological Association

The American Urological Association (AUA; 2017) guideline on renal masses and localized renal cancer affirms that partial nephrectomy should be prioritized for the management of cT1a renal masses when intervention is indicated. Thermal ablation should be considered "as an alternate approach for the management of cT1a renal masses <3 cm in size." The guidelines were updated in 2021 and recommendations are generally consistent with what was published in the 2017 guideline. The 2021 AUA guideline explicitly states that RFA and cryoablation may be offered as options to patients who elect thermal ablation.

American Thyroid Association

The American Thyroid Association (2015) guideline on the management of thyroid nodules and differentiated thyroid cancer provides recommendations for management. Patients with a benign cytology diagnosis or those very unlikely to be malignant (eg, purely cystic nodule) should undergo surveillance with the frequency determined by the level of suspicion for a missed malignancy. Medical or surgical intervention is considered if the nodules are large (>4 cm), causing compressive or structural symptoms, or if there is clinical concern. Recurrent cystic thyroid nodules with benign cytology should be considered for surgical removal or percutaneous ethanol injection. For differentiated thyroid cancer, "localized treatments with thermal (radiofrequency or cryo-) ablation, ethanol ablation, or chemoembolization may be beneficial in patients with a single or a few metastases and in those with metastases at high risk of local complications."

National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN) guidelines for the treatment of NSCLC (v.3.2023) state: "For medically operable disease, resection is the preferred local treatment modality (other modalities include SABR [stereotactic ablative radiotherapy], thermal ablation such as radiofrequency ablation, and cryotherapy)." For patients who are not amenable to surgery image-guided thermal ablation therapy (IGTA; includes RFA, microwave ablation, and cryoablation) may be considered. The guidance states "IGTA is an option for the management of NSCLC lesions <3 cm. Ablation for NSCLC lesions >3 cm may be associated with higher rates of local recurrence and complications."

The NCCN guidelines for thyroid carcinoma (v.3.2023) indicate that local therapies such as RFA may be considered for locoregional recurrence of thyroid carcinoma-papillary carcinoma in select patients with limited burden nodal disease. Additionally, local therapies, including RFA, can be considered in those with metastatic disease.

The NCCN guidelines (v.1.2024) for renal cancer indicate that "thermal ablation (eg, cryosurgery, radiofrequency ablation, microwave ablation) is an option for the management of clinical stage T1 renal lesions. Thermal ablation is an option for clinical T1b masses in select patients not eligible for surgery. Biopsy of lesions is recommended to be done prior to or at time

of ablation. Ablative techniques may require multiple treatments to achieve the same oncologic outcomes as conventional surgery."

The NCCN colon cancer guidelines (v.2.2023), state that "resection is the standard approach for the local treatment of resectable metastatic disease. However, patients with liver or lung oligometastases can also be considered for tumor ablation therapy, particularly in cases that may not be optimal for resection." "There is extensive evidence on the use of RFA as a reasonable treatment option for non-surgical candidates and recurrent disease after hepatectomy with small liver metastases that can be treated with clear margins."

The NCCN guidelines for head and neck cancers (v.2.2023), breast cancer (v.4.2023), bone cancer (v.1.2024), and pancreatic adenocarcinoma (v.2.2023) do not mention RFA.

National Institute for Clinical Excellence

NICE guidance issued in 2004 indicates that "current evidence on the safety and efficacy of computed tomography (CT)-guided thermocoagulation of osteoid osteoma appears adequate to support its use, provided that the normal arrangements are in place for consent, audit and clinical governance."

The NICE guidance updated in 2010 indicates that "evidence on the safety and efficacy of percutaneous radiofrequency ablation (RFA) for renal cancer in the short and medium term appears adequate to support the use of this procedure provided that normal arrangements are in place for clinical governance, consent and audit, and provided that patients are followed up in the long term.

The NICE guidance on RFA for primary and secondary lung cancers issued in 2010 states, "Current evidence on the efficacy of percutaneous radiofrequency ablation (RFA) for primary or secondary lung cancers is adequate in terms of tumor control." The NICE also indicates RFA may "be used in patients with small, early-stage lung cancers or small numbers of lung metastases who are unsuitable for, or prefer not to undergo, surgery. It may also have a place in multi-modality treatment of more advanced primary lung cancers." The guidance warns of complications such as pneumothorax, which can result in serious consequences among lung cancer patients.

The NICE guidance (2016) on benign thyroid nodules stated: "Current evidence on the safety and efficacy of ultrasound-guided percutaneous radiofrequency ablation ... is adequate to support the use of this procedure...."

Society of Interventional Radiology

The Society of Interventional Radiology (2020) published a position statement on the role of percutaneous ablation in renal cell carcinoma. Their relevant recommendations are as follows:

- "In patients with small renal tumors (stage T1a), percutaneous thermal ablation is a safe and effective treatment with fewer complications than nephrectomy and acceptable long-term oncological and survival outcomes. (Level of Evidence: C; Strength of Recommendation: Moderate)"

- "In selected patients with suspected T1a renal cell carcinoma, percutaneous thermal ablation should be offered over active surveillance. (Level of Evidence: C; Strength of Recommendation: Moderate)"
- "In high-risk patients with T1b renal cell carcinoma who are not surgical candidates, percutaneous thermal ablation may be an appropriate treatment option; however, further research in this area is required. (Level of Evidence: D; Strength of Recommendation: Weak)"
- "Radiofrequency ablation, cryoablation, and microwave ablation are all appropriate modalities for thermal ablation, and method of ablation should be left to the discretion of the operating physician. (Level of Evidence: D; Strength of Recommendation: Weak)"

U.S. Preventive Services Task Force Recommendations

Not applicable.

KEY WORDS:

Renal cell carcinoma, RCC, radiofrequency ablation, RF, RF ablation, RFA, percutaneous radiofrequency ablation, pulmonary tumor, lung cancer, breast cancer, head and neck, cancer, adrenal, ovary, pelvic and/or abdominal tumor, osteoid tumor, bone metastases, palliation of pain, thyroid cancer, osteoid osteoma, metastatic bone cancer

APPROVED BY GOVERNING BODIES:

The U.S. Food and Drug Administration (FDA) issued a statement in September 2008, concerning the regulatory status of RFA. The FDA has cleared RFA devices for the general indication of soft tissue cutting, coagulation, and ablation by thermal coagulation necrosis. Under this general indication, RFA can be used to ablate tumors, including lung tumors. Some RFA devices have been cleared for additional specific treatment indications, including partial or complete ablation of nonresectable liver lesions and palliation of pain associated with metastatic lesions involving bone. The FDA has not cleared any RFA devices for the specific treatment indication of partial or complete ablation of lung tumors, citing lack of sufficient clinical data to establish safety and effectiveness for this purpose. The FDA has received reports of death and serious injuries associated with the use of RFA devices in the treatment of lung tumors.

BENEFIT APPLICATION:

Coverage is subject to member's specific benefits. Group-specific policy will supersede this policy when applicable.

CURRENT CODING:

CPT codes

19499	Unlisted Procedure, Breast
20982	Ablation therapy for reduction or eradication of 1 or more bone tumors (e.g., metastasis) including adjacent soft tissue when involved by tumor extension, percutaneous, including imaging guidance when performed; radiofrequency
32998	Ablation therapy for reduction or eradication of one or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, unilateral; radiofrequency
50542	Laparoscopy, surgical; ablation of renal mass lesion(s)
50592	Ablation, one or more renal tumor(s), percutaneous, unilateral, radiofrequency
76940	Ultrasound guidance for, and monitoring of, parenchymal tissue ablation

REFERENCES:

1. Albisinni U, Facchini G, Spinnato P, et al. Spinal osteoid osteoma: efficacy and safety of radiofrequency ablation. *Skeletal Radiol.* Aug 2017;46(8):1087-1094.
2. Andrews JR, Atwell T, Schmit G, et al. Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. *Eur Urol.* Aug 2019; 76(2): 244-251.
3. Baek JH, Lee JH, Sung JY et al. Complications encountered in the treatment of benign thyroid nodules with US-guided radiofrequency ablation: a multicenter study. *Radiology* 2012; 262(1):335-42.
4. Bilal H, Mahmood S, Rajashanker B et al. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer? *Interact Cardiovasc Thorac Surg* 2012; 15(2):258-65.
5. Campbell S, Uzzo RG, Allaf ME, et al. Renal Mass and Localized Renal Cancer: AUA Guideline. *J Urol.* Sep 2017; 198(3):520-529.
6. Campbell SC, Clark PE, Chang SS, et al. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. *J Urol.* Aug 2021; 206(2): 199-208.
7. Cantore M, Girelli R, Mambrini A et al. Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma. *Br J Surg* Aug 2012; 99(8):1083-8.
8. Chan VO, McDermott S, Malone DE et al. Percutaneous radiofrequency ablation of lung tumors: evaluation of the literature using evidence-based techniques. *J Thorac Imaging* Feb 2011; 26(1):18-26.

9. Chen F, Tian G, Kong D, et al. Radiofrequency ablation for treatment of benign thyroid nodules: A PRISMAcompliant systematic review and meta-analysis of outcomes. *Medicine (Baltimore)*. Aug 2016;95(34):e4659.
10. Cho SJ, Baek JH, Chung SR, et al. Long-Term Results of Thermal Ablation of Benign Thyroid Nodules: A Systematic Review and Meta-Analysis. *Endocrinol Metab (Seoul)*. Jun 2020; 35(2): 339-350.
11. Dai Y, Covarrubias D, Uppot R, et al. Image-guided percutaneous radiofrequency ablation of central renal cell carcinoma: assessment of clinical efficacy and safety in 31 tumors. *J Vasc Interv Radiol*. Dec 2017;28(12):1643- 1650.
12. Donington J, Ferguson M, Mazzone P et al. American College of Chest Physicians and Society of Thoracic Surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer. *Chest* Dec 2012; 142(6):1620-35.
13. Dvorak P, Hoffmann P, Brodak M, et al. Percutaneous radiofrequency and microwave ablation in the treatment of renal tumors - 10 years of experience. *Wideochir Inne Tech Maloinwazyjne*. Dec 2017;12(4):394-402.
14. El Dib R, Touma NJ, Kapoor A. Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies. *BJU Int* Aug 2012; 110(4):510-6.
15. Fuller CW, Nguyen SA, Lohia S, et al. Radiofrequency ablation for treatment of benign thyroid nodules: systematic review. *Laryngoscope*. Jan 2014; 124(1):346-353.
16. Hasegawa T, Takaki H, Kodama H, et al. Three-year Survival Rate after Radiofrequency Ablation for Surgically Resectable Colorectal Lung Metastases: A Prospective Multicenter Study. *Radiology*. Mar 2020; 294(3): 686-695.
17. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid*. Jan 2016; 26(1): 1-133.
18. Howard JM, Nandy K, Woldu SL, et al. Demographic Factors Associated With Non-Guideline-Based Treatment of Kidney Cancer in the United States. *JAMA Netw Open*. Jun 01 2021; 4(6): e2112813.
19. Howington JA, Blum MG, Chang AC et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* May 2013; 143(5 Suppl):e278S-313S.
20. Huang L, Han Y, Zhao J et al. Is radiofrequency thermal ablation a safe and effective procedure in the treatment of pulmonary malignancies? *Eur J Cardiothorac Surg* 2011; 39(3):348-51.
21. Huh JY, Baek JH, Choi H et al. Symptomatic benign thyroid nodules: efficacy of additional radiofrequency ablation treatment session--prospective randomized study. *Radiology* 2012; 263(3):909-16.

22. Iannuccilli JD, Dupuy DE, Beland MD, et al. Effectiveness and safety of computed tomography-guided radiofrequency ablation of renal cancer: a 14-year single institution experience in 203 patients. *Eur Radiol.* Jun 2016; 26(6):1656-1664.
23. IOM (Institute of Medicine). 2011. *Clinical Practice Guidelines We Can Trust*. Washington, DC: The National Academies Press.
24. Ito T, Oura S, Nagamine S, et al. Radiofrequency ablation of breast cancer: a retrospective study. *Clin Breast Cancer.* Aug 2018;18(4):e495-e500.
25. Jatoi I, Sung H, Jemal A. The Emergence of the Racial Disparity in U.S. Breast-Cancer Mortality. *N Engl J Med.* Jun 23 2022; 386(25): 2349-2352.
26. Jung SL, Baek JH, Lee JH, et al. Efficacy and safety of radiofrequency ablation for benign thyroid nodules: a prospective multicenter study. *Korean J Radiol.* Jan-Feb 2018;19(1):167-174.
27. Katsanos K, Mailli L, Krokidis M, et al. Systematic review and meta-analysis of thermal ablation versus surgical nephrectomy for small renal tumours. *Cardiovasc Intervent Radiol.* Apr 2014; 37(2):427-437.
28. Khan AN, et al. Osteoid osteoma, www.emedicine.com/radio/topic498.htm.
29. Kim JH, Yoo WS, Park YJ, et al. Efficacy and safety of radiofrequency ablation for treatment of locally recurrent thyroid cancers smaller than 2 cm. *Radiology.* Sep 2015; 276(3):909-918.
30. Kinoshita T, Iwamoto E, Tsuda H et al. Radiofrequency ablation as local therapy for early breast carcinomas. *Breast Cancer* Jan 2011; 18(1):10-7.
31. Knudsen M, Riishede A, Lucke A, et al. Computed tomography-guided radiofrequency ablation is a safe and effective treatment of osteoid osteoma located outside the spine. *Dan Med J.* May 2015; 62(5).
32. Lanza E, Thouvenin Y, Viala P, et al. Osteoid Osteoma Treated by Percutaneous Thermal Ablation: When Do We Fail? A Systematic Review and Guidelines for Future Reporting. *Cardiovasc Intervent Radiol.* Dec 2014; 37(6): 1530-9.
33. Lassalle L, Campagna R, Corcos G, et al. Therapeutic outcome of CT-guided radiofrequency ablation in patients with osteoid osteoma. *Skeletal Radiol.* Jul 2017;46(7):949-956.
34. Levy J, Hopkins T, Morris J, et al. Radiofrequency Ablation for the Palliative Treatment of Bone Metastases: Outcomes from the Multicenter OsteoCool Tumor Ablation Post-Market Study (OPuS One Study) in 100 Patients. *J Vasc Interv Radiol.* Nov 2020; 31(11): 1745-1752.
35. Li P, Xiao-Yin T, Cui D, et al. Evaluation of the safety and efficacy of percutaneous radiofrequency ablation for treating multiple breast fibroadenoma. *J Cancer Res Ther.* Dec 2016;12(Supplement):C138-C142.
36. Lim HK, Lee JH, Ha EJ et al. Radiofrequency ablation of benign non-functioning thyroid nodules: 4- year follow-up results for 111 patients. *Eur Radiol* Apr 2013; 23(4):1044-9.
37. Liu B, Mo C, Wang W, et al. Treatment outcomes of percutaneous radiofrequency ablation versus adrenalectomy for adrenal metastases: a retrospective comparative study. *J Endocrinol Invest.* Sep 2020; 43(9): 1249-1257.

38. Liu SY, Chu CM, Kong AP, et al. Radiofrequency ablation compared with laparoscopic adrenalectomy for aldosterone-producing adenoma. *Br J Surg.* Oct 2016;103(11):1476-1486.
39. Marshall HR, Shakeri S, Hosseiny M, et al. Long-Term Survival after Percutaneous Radiofrequency Ablation of Pathologically Proven Renal Cell Carcinoma in 100 Patients. *J Vasc Interv Radiol.* Jan 2020; 31(1): 15-24.
40. Morris CS, Baerlocher MO, Dariushnia SR, et al. Society of Interventional Radiology Position Statement on the Role of Percutaneous Ablation in Renal Cell Carcinoma: Endorsed by the Canadian Association for Interventional Radiology and the Society of Interventional Oncology. *J Vasc Interv Radiol.* Feb 2020; 31(2): 189-194.e3.
41. Mylona S, Karagiannis G, Patsoura S et al. Palliative treatment of rectal carcinoma recurrence using radiofrequency ablation. *Cardiovasc Intervent Radiol* Aug 2012; 35(4):875-82.
42. Na DG, Lee JH, Jung SL et al. Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: consensus statement and recommendations. *Korean J Radiol* Mar-Apr 2012; 13(2):117-25.
43. National Cancer Institute. SEER Cancer Stat Facts: Kidney and Renal Pelvis Cancer. 2023. seer.cancer.gov/statfacts/html/kidrp.html.
44. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2023. Updated April 25, 2023. www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
45. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-small cell lung cancer. Version 3.2023. Updated April 13, 2023. www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
46. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version 3.2023. Updated July 27, 2023. www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf.
47. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 1.2024. Updated June 21, 2023. www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.
48. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 4.2023. Updated March 23, 2023. www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
49. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Bone Cancer. Version 3.2023. Updated April 4, 2023. www.nccn.org/professionals/physician_gls/pdf/bone.pdf.
50. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Head and Neck Cancers. Version 2.2023. Updated May 15, 2023. www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.
51. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Pancreatic Adenocarcinoma. Version 2.2023. Updated June 19, 2023. www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.

52. National Institute for Clinical Excellence (NICE). Computed tomography-guided thermocoagulation of osteoid osteoma [IPG53]. 2004. Available online at: www.nice.org.uk/nicemedia/pdf/IPG053guidance.pdf.
53. National Institute for Clinical Excellence (NICE). Percutaneous radiofrequency ablation for primary and secondary lung cancers [IPG372]. 2010. Available online at: www.nice.org.uk/guidance/IPG372.
54. National Institute for Clinical Excellence (NICE). Percutaneous radiofrequency ablation of renal cancer [IPG353]. 2010. Available online at: www.nice.org.uk/guidance/IPG353.
55. National Institute for Health and Care Excellence (NICE). Ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules [IPG562]. 2016; www.nice.org.uk/guidance/IPG562.
56. Orloff LA, Noel JE, Stack BC, et al. Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Associazione MediciEndocrinologi, British Association of Endocrine and Thyroid Surgeons, European Thyroid Association, Italian Society of Endocrine Surgery Units, Korean Society of Thyroid Radiology, Latin American Thyroid Society, and Thyroid Nodules Therapies Association. *Head Neck*. Mar 2022; 44(3): 633-660.
57. Owen RP, Khan SA, Negassa A et al. Radiofrequency ablation of advanced head and neck cancer. *Arch Otolaryngol Head Neck Surg* May 2011; 137(5):493-8.
58. Pantelidou M, Challacombe B, McGrath A, et al. Percutaneous radiofrequency ablation versus robotic-assisted partial nephrectomy for the treatment of small renal cell carcinoma. *Cardiovasc Intervent Radiol*. Nov 2016;39(11):1595-1603.
59. Park BK, Gong IH, Kang MY, et al. RFA versus robotic partial nephrectomy for T1a renal cell carcinoma: a propensity score-matched comparison of mid-term outcome. *Eur Radiol*. Jul 2018;28(7):2979-2985.
60. Peek MCL, Ahmed M, Napoli A, et al. Minimally invasive ablative techniques in the treatment of breast cancer: a systematic review and meta-analysis. *Int J Hyperthermia*. Mar 2 2017;33(2):191-202.
61. Physician Data Query (PDQ). Non-small cell lung cancer treatment (PDQ®). 2008. Available online at: www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/HealthProfessional.
62. Ratko TA, Vats V, Brock J et al. Local Nonsurgical Therapies for Stage I and Symptomatic Obstructive Non-Small-Cell Lung Cancer. Rockville, MD; Agency for Healthcare Research and Quality, 2013.
63. Rey VE, Labrador R, Falcon M, et al. Transvaginal Radiofrequency Ablation of Myomas: Technique, Outcomes, and Complications. *J Laparoendosc Adv Surg Tech A*. 2019 Jan;29(1):24-28.
64. Rimondi E, Mavrogenis AF, Rossi G et al. Radiofrequency ablation for non-spinal osteoid osteomas in 557 patients. *Eur Radiol* Jan 2012; 22(1):181-8.

65. Ripley RT, Gajdos C, Reppert AE et al. Sequential radiofrequency ablation and surgical debulking for unresectable colorectal carcinoma: Thermo-surgical ablation. *J Surg Oncol* Feb 2013; 107(2):144-7.
66. Rombouts SJ, Vogel JA, van Santvoort HC, et al. Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. *Br J Surg*. Feb 2015; 102(3):182-193.
67. Sahin C, Oc Y, Ediz N, et al. The safety and the efficacy of computed tomography guided percutaneous radiofrequency ablation of osteoid osteoma. *Acta Orthop Traumatol Turc*. Sep 2019; 53(5): 360-365.
68. Schlijper RC, Grutters JP, Houben R et al. What to choose as radical local treatment for lung metastases from colo-rectal cancer: Surgery or radiofrequency ablation? *Cancer Treat Rev* Feb 2014; 40(1): 60-7.
69. Tordjman M, Perronne L, Madelin G, et al. CT-guided radiofrequency ablation for osteoid osteomas: a systematic review. *EurRadiol*. Nov 2020; 30(11): 5952-5963.
70. U.S. Food and Drug Administration (FDA). FDA Public Health Notification: Radiofrequency ablation of lung tumors – Clarification of regulatory status. www.fda.gov/medicaldevices/safety/alertsandnotices/publichealthnotifications/ucm061985.htm.
71. Uhlig J, Strauss A, Rücker G, et al. Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis. *Eur Radiol*. 2019 Mar;29(3):1293-1307.
72. Van Poppel H, Becker F, Cadeddu JA et al. Treatment of localised renal cell carcinoma. *Eur Urol* 2011 Oct; 60(4):662-72.
73. Wang S, Qin C, Peng Z, et al. Radiofrequency ablation versus partial nephrectomy for the treatment of clinical stage 1 renal masses: a systematic review and meta-analysis. *Chin Med J (Engl)*. Jul 2014; 127(13):2497-2503.
74. Wilson M, Korourian S, Boneti C et al. Long-term results of excision followed by radiofrequency ablation as the sole means of local therapy for breast cancer. *Ann Surg Oncol* Oct 2012; 19(10):3192-8.
75. Xia LY, Hu QL, Xu WY. Efficacy and Safety of Radiofrequency Ablation for Breast Cancer Smaller Than 2 cm: A Systematic Review and Meta-Analysis. *Front Oncol*. 2021; 11: 651646.
76. Yanagisawa T, Mori K, Kawada T, et al. Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis. *Urol Oncol*. Jul 2022; 40(7): 315-330.
77. Yang MH, Tyan YS, Huang YH, et al. Comparison of radiofrequency ablation versus laparoscopic adrenalectomy for benign aldosterone-producing adenoma. *Radiol Med*. Oct 2016;121(10):811-819.
78. Yedjou CG, Sims JN, Miele L, et al. Health and Racial Disparity in Breast Cancer. *Adv Exp Med Biol*. 2019; 1152: 31-49.
79. Yin G, Chen M, Yang S, et al. Treatment of uterine myomas by radiofrequency thermal ablation: a 10-year retrospective cohort study. *Reprod Sci*. May 2015; 22(5):609-614.

POLICY HISTORY:

Adopted for Blue Advantage, March 2005
Available for comment May 1-June 14, 2005
Medical Policy Group, January 2006 (from MP# 149)
Medical Policy Group, December 2006
Available for comment January 11-February 24, 2007
Medical Policy Group, October 2007 (from MP# 149)
Available for comment November 17-December 31, 2007 (from MP# 149)
Medical Policy Group, December 2007
Medical Policy Group, March 2009
Available for comment April 3-May 18, 2009
Medical Policy Group, October 2009 (from MP# 149)
Available for comment November 6-December 21, 2009 (from MP# 149)
Medical Policy Group, October 2010
Medical Policy Group, March 2011 (from MP# 149)
Available for comment April 4 – May 18, 2011 (from MP# 149)
Medical Policy Group, January 2012:
Available for comment February 9 – March 26, 2012
Medical Policy Group, March 2013
Medical Policy Group, October 2013
Medical Policy Group, November 2014
Medical Policy Group, February 2015
Available for comment March 12 – April 26, 2015
Medical Policy Group, April 2015
Medical Policy Group, September 2015
Medical Policy Group, September 2016
Medical Policy Group, September 2017
Medical Policy Group, December 2017
Medical Policy Group, April 2018
Available for comment April 17 through May 31, 2018
Medical Policy Group, September 2018 **(4)**: Updates to Description, Policy, Key Points, and References. Removed policy statements effective for dates of service January 1, 2012 through April 26, 2015. No change to current policy statements.
Medical Policy Group, September 2019
Medical Policy Group, September 2020
Medical Policy Group, September 2021
Medical Policy Group, September 2022
Medical Policy Group, September 2023
UM Committee, December 2023: Policy approved by UM Committee for use for Blue Advantage business.

This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member's plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield's administration of plan contracts.